However, unlike hematoxylin-and-eosin (H&E) staining and ER/HER2/PR immunohistochemistry staining of tumor samples, the determination of ER pathway activity requires transcriptomic analyses that are not part of standard diagnostic procedures; thus, these data are usually unavailable. The gene discussed is ERBB2; the disease is neoplasm.